ChromaDex holds 2022 annual meeting; re-elects seven directors, appoints Steven Rubin as Lead Independent Director

Niagen Bioscience, Inc.

All seven director nominees elected at June 16 annual meeting; votes ranged from ~28.3M to ~37.3M for.
Shareholders ratified Marcum LLP as auditor for FY2022 with 47.7M for, 1.8M against.
Advisory say-on-pay proposal passed with 36.0M for, 1.1M against.
Board appointed Steven Rubin as Lead Independent Director following Kurt Gustafson's departure.
Board committee assignments reconstituted; Rubin chairs Audit, Patrick chairs Compensation, Cohen chairs Nominating.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.